This HTML5 document contains 146 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00764/identifier/drugbank/
n5http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00764/identifier/national-drug-code-directory/
n9http://linked.opendata.cz/resource/drugbank/mixture/
n28http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB00764/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/patent/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00764/identifier/pharmgkb/
n25http://linked.opendata.cz/resource/drugbank/medicinal-product/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00764/identifier/wikipedia/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n20http://www.drugs.com/cdi/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00764/identifier/pdb/
n22http://www.rxlist.com/cgi/generic2/
n8http://linked.opendata.cz/resource/drugbank/property/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00764/identifier/kegg-compound/
n12http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00764
rdf:type
n3:Drug
n3:description
Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. he antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
n3:dosage
n6:271B5C00-363D-11E5-9242-09173F13E4C5 n6:271B5C01-363D-11E5-9242-09173F13E4C5 n6:271B5C02-363D-11E5-9242-09173F13E4C5 n6:271B5BFB-363D-11E5-9242-09173F13E4C5 n6:271B5BFC-363D-11E5-9242-09173F13E4C5 n6:271B5BFD-363D-11E5-9242-09173F13E4C5 n6:271B5BFE-363D-11E5-9242-09173F13E4C5 n6:271B5BFA-363D-11E5-9242-09173F13E4C5 n6:271B5C03-363D-11E5-9242-09173F13E4C5 n6:271B5C04-363D-11E5-9242-09173F13E4C5 n6:271B5BFF-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
5.8 hours
n3:indication
The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.
n3:manufacturer
n13:271B5BD5-363D-11E5-9242-09173F13E4C5 n13:271B5BD6-363D-11E5-9242-09173F13E4C5 n13:271B5BD4-363D-11E5-9242-09173F13E4C5 n13:271B5BDE-363D-11E5-9242-09173F13E4C5 n13:271B5BDF-363D-11E5-9242-09173F13E4C5 n13:271B5BDC-363D-11E5-9242-09173F13E4C5 n13:271B5BDD-363D-11E5-9242-09173F13E4C5 n13:271B5BD7-363D-11E5-9242-09173F13E4C5 n13:271B5BDA-363D-11E5-9242-09173F13E4C5 n13:271B5BDB-363D-11E5-9242-09173F13E4C5 n13:271B5BD8-363D-11E5-9242-09173F13E4C5 n13:271B5BD9-363D-11E5-9242-09173F13E4C5
owl:sameAs
n27:DB00764 n28:DB00764
dcterms:title
Mometasone
adms:identifier
n15:MOF n16:6970 n17:C07816 n18:0085-0370-01 n19:DB00764 n21:Mometasone n23:PA450541
n3:mechanismOfAction
Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A<sub>2</sub> inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone.
n3:packager
n13:271B5BCD-363D-11E5-9242-09173F13E4C5 n13:271B5BCE-363D-11E5-9242-09173F13E4C5 n13:271B5BC1-363D-11E5-9242-09173F13E4C5 n13:271B5BD3-363D-11E5-9242-09173F13E4C5 n13:271B5BD1-363D-11E5-9242-09173F13E4C5 n13:271B5BD2-363D-11E5-9242-09173F13E4C5 n13:271B5BCF-363D-11E5-9242-09173F13E4C5 n13:271B5BC8-363D-11E5-9242-09173F13E4C5 n13:271B5BD0-363D-11E5-9242-09173F13E4C5 n13:271B5BC9-363D-11E5-9242-09173F13E4C5 n13:271B5BC6-363D-11E5-9242-09173F13E4C5 n13:271B5BC7-363D-11E5-9242-09173F13E4C5 n13:271B5BC4-363D-11E5-9242-09173F13E4C5 n13:271B5BC5-363D-11E5-9242-09173F13E4C5 n13:271B5BC2-363D-11E5-9242-09173F13E4C5 n13:271B5BC3-363D-11E5-9242-09173F13E4C5 n13:271B5BCC-363D-11E5-9242-09173F13E4C5 n13:271B5BCA-363D-11E5-9242-09173F13E4C5 n13:271B5BCB-363D-11E5-9242-09173F13E4C5
n3:patent
n10:5394868 n10:6503537 n10:2282360 n10:2091360
n3:synonym
Mometason Mométasone (furoate de) Mometasona Mometasoni furoas Mometasonfuroat Mometasone Furoate Mométasone (+)-Mometasone Mometasonum Mometasone Furoate Hydrate Mometason furoat-1-Wasser
n3:toxicity
The potential for acute toxic effects following overdose with the mometasone inhaler is low. However, habitual overuse of the product can cause symptoms of steroid overload, including menstrual irregularities, acne, obesity, and muscle weakness. Single oral doses up to 8000 &micro;g have been studied on human volunteers with no adverse events reported.
n4:hasAHFSCode
n5:84-06-00 n5:52-08-08
n3:mixture
n9:271B5BBF-363D-11E5-9242-09173F13E4C5 n9:271B5BC0-363D-11E5-9242-09173F13E4C5 n9:271B5BBE-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
98% to 99% (in a concentration range of 5 to 500 ng/mL).
n3:synthesisReference
Pui-Ho Yuen, Charles Eckhart, Teresa Etlinger, Nancy Levine, "Mometasone furoate monohydrate, process for making same and pharmaceutical compositions." U.S. Patent US6127353, issued April, 1988.
foaf:page
n12:nas1518.shtml n20:mometasone-spray.html n22:momet1.htm
n3:IUPAC-Name
n8:271B5C09-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B5C0F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B5C0E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B5C0B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B5C0C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B5C0D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B5C1F-363D-11E5-9242-09173F13E4C5 n8:271B5C07-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B5C21-363D-11E5-9242-09173F13E4C5 n8:271B5C08-363D-11E5-9242-09173F13E4C5 n8:271B5C05-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B5C06-363D-11E5-9242-09173F13E4C5
n4:hasATCCode
n7:D07AC13 n7:R03BA07 n7:D07XC03 n7:R01AD09
n3:H-Bond-Acceptor-Count
n8:271B5C15-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B5C16-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B5C10-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B5C11-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B5C13-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B5C12-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B5C14-363D-11E5-9242-09173F13E4C5
n3:absorption
Nasal spray is virtually undetectable in plasma
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
105102-22-5
n3:containedIn
n25:271B5BE6-363D-11E5-9242-09173F13E4C5 n25:271B5BE7-363D-11E5-9242-09173F13E4C5 n25:271B5BE4-363D-11E5-9242-09173F13E4C5 n25:271B5BE5-363D-11E5-9242-09173F13E4C5 n25:271B5BE2-363D-11E5-9242-09173F13E4C5 n25:271B5BE3-363D-11E5-9242-09173F13E4C5 n25:271B5BE0-363D-11E5-9242-09173F13E4C5 n25:271B5BE1-363D-11E5-9242-09173F13E4C5 n25:271B5BEE-363D-11E5-9242-09173F13E4C5 n25:271B5BEF-363D-11E5-9242-09173F13E4C5 n25:271B5BEC-363D-11E5-9242-09173F13E4C5 n25:271B5BED-363D-11E5-9242-09173F13E4C5 n25:271B5BEA-363D-11E5-9242-09173F13E4C5 n25:271B5BEB-363D-11E5-9242-09173F13E4C5 n25:271B5BE8-363D-11E5-9242-09173F13E4C5 n25:271B5BE9-363D-11E5-9242-09173F13E4C5 n25:271B5BF6-363D-11E5-9242-09173F13E4C5 n25:271B5BF7-363D-11E5-9242-09173F13E4C5 n25:271B5BF4-363D-11E5-9242-09173F13E4C5 n25:271B5BF5-363D-11E5-9242-09173F13E4C5 n25:271B5BF2-363D-11E5-9242-09173F13E4C5 n25:271B5BF3-363D-11E5-9242-09173F13E4C5 n25:271B5BF0-363D-11E5-9242-09173F13E4C5 n25:271B5BF1-363D-11E5-9242-09173F13E4C5 n25:271B5BF8-363D-11E5-9242-09173F13E4C5 n25:271B5BF9-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n8:271B5C1B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B5C1D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B5C1E-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B5C20-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B5C1A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B5C19-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B5C1C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B5C0A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B5C17-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B5C18-363D-11E5-9242-09173F13E4C5